多發性硬化症治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

2023 年，全球多發性硬化症治療市場估值約255 億美元。一種慢性自體免疫疾病）的一系列治療和藥物。這種情況會導致髓鞘（神經纖維的保護層）惡化，擾亂大腦和身體之間的溝通。

多發性硬化症患病率的增加極大地推動了市場的成長。例如，世界衛生組織 (WHO) 報告稱，全球有超過 280 萬人受到多發性硬化症的影響，其中年輕人和女性更容易受到影響。這種不斷上升的盛行率擴大了對有效治療方法的需求，推動了針對不斷擴大的患者群體的創新治療方法的研究和開發。

多發性硬化症藥物開發的最新進展顯著增強了疾病管理。在過去的十年中，新療法在滿足不同患者需求方面表現出了卓越的功效。這些進步正在重塑治療格局，引入有針對性的、便利的、個人化的選擇，不僅改善患者的治療結果，也提高他們的生活品質。

整個產業分為藥品類別、給藥途徑、配銷通路和地區。

市場將藥物類別分為免疫抑制劑、免疫促效劑、免疫調節劑、皮質類固醇等。預測顯示，到 2032 年，免疫調節劑市場將達到 236 億美元。它們調節免疫反應，從而降低復發頻率和嚴重程度，減少神經系統惡化事件，並增強整體疾病管理。

市場區隔基於口服和注射劑的給藥途徑。注射劑又分為肌肉注射、皮下注射和靜脈注射。口服藥物在 2023 年創造了 149 億美元的收入。它們使患者能夠在家中自我管理，無需醫療監督，從而提高他們的生活品質。

在美國，多發性硬化症治療市場預計到 2032 年將達到 133 億美元。美國國家多發性硬化症協會的數據強調了這一點，並指出，2019 年，美國有近 100 萬人被診斷出來，這增加了對先進療法的需求並推動了市場創新。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 多發性硬化症患病率增加
    • 藥物開發的進展
    • 日益關注個人化醫療
    • 老年人口不斷增加
  • 產業陷阱與挑戰
    • 藥品成本高
    • 與藥物相關的副作用
• 成長潛力分析
• 技術景觀
• 管道分析
• 監管環境
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 免疫抑制劑
• 免疫增強劑
• 免疫調節劑
• 皮質類固醇
• 其他藥物類別

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

• 主要趨勢
• 口服
• 注射劑
  • 肌肉注射
  • 皮下
  • 靜脈

第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥房
• 網路藥房

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbvie Inc.
• Amgen Inc.
• Acorda Therapeutics, Inc.
• Biogen Inc.
• Bayer AG
• Bristol-Myers Squibb Company.
• F. Hoffman-La Roche Ltd
• Johnson and Johnson
• Merck and Co., Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceuticals Company Limited.
• Pfizer Inc.
• Sanofi
• Viatris Inc.

The Global Multiple Sclerosis Therapeutic Market was valued at approximately USD 25.5 billion in 2023. Projections indicate a growth rate of 4.7% CAGR from 2024 to 2032. Multiple sclerosis therapeutics refer to a range of treatments and medications aimed at managing multiple sclerosis, a chronic autoimmune disorder impacting the central nervous system (CNS). This condition deteriorates the myelin sheath, which is the nerve fibers' protective covering, disrupting communication between the brain and body.

The increasing prevalence of multiple sclerosis significantly propels the market growth. For example, the World Health Organization (WHO) reports that over 2.8 million individuals globally are affected by multiple sclerosis, with young adults and females being more susceptible. This rising prevalence amplifies the demand for effective therapeutics, fueling research and development for innovative treatments catering to this expanding patient base.

Recent advancements in drug development for multiple sclerosis have markedly enhanced disease management. In the last decade, new therapies have showcased superior efficacy for catering to diverse patient needs. Such advancements are reshaping the treatment landscape, introducing targeted, convenient, and personalized options that not only improve patient outcomes but also elevate their quality of life.

The overall industry is divided into drug class, route of administration, distribution channel, and region.

The market categorizes drug classes into immunosuppressants, immunostimulants, immunomodulators, corticosteroids, and others. Forecasts suggest the immunomodulators segment will hit USD 23.6 billion by 2032. Immunomodulators, including interferon beta and glatiramer acetate, play a pivotal role in managing multiple sclerosis. They modulate the immune response, leading to reduced relapse frequency and severity, fewer neurological deterioration episodes, and enhanced overall disease management.

The market segments based on administration routes into oral and injectables. The injectables further divide into intramuscular, subcutaneous, and intravenous. The oral segment generated USD 14.9 billion in 2023. Oral medications, being more user-friendly than injectables, boost patient compliance. They empower patients to self-administer at home, free from medical supervision, thus enhancing their quality of life.

In the U.S., the multiple sclerosis therapeutic market is set to reach USD 13.3 billion by 2032. The country's high multiple sclerosis prevalence significantly fuels this market growth. Data from the National Multiple Sclerosis Society highlights this, noting that in 2019, nearly 1 million individuals in the U.S. were diagnosed, intensifying the demand for advanced therapies and driving market innovation.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of multiple sclerosis
    • 3.2.1.2 Advancements in drug development
    • 3.2.1.3 Growing focus on personalized medicine
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of the drugs
    • 3.2.2.2 Side effects associated with the medication
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Pipeline analysis
• 3.6 Regulatory landscape
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Immunosuppressants
• 5.3 Immunostimulants
• 5.4 Immunomodulators
• 5.5 Corticosteroids
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectables
  • 6.3.1 Intramuscular
  • 6.3.2 Subcutaneous
  • 6.3.3 Intravenous

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbvie Inc.
• 9.2 Amgen Inc.
• 9.3 Acorda Therapeutics, Inc.
• 9.4 Biogen Inc.
• 9.5 Bayer AG
• 9.6 Bristol-Myers Squibb Company.
• 9.7 F. Hoffman-La Roche Ltd
• 9.8 Johnson and Johnson
• 9.9 Merck and Co., Inc.
• 9.10 Novartis AG
• 9.11 Teva Pharmaceutical Industries Ltd.
• 9.12 Takeda Pharmaceuticals Company Limited.
• 9.13 Pfizer Inc.
• 9.14 Sanofi
• 9.15 Viatris Inc.